← All indications
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
Subtype terms (1)
More specific conditions that are subtypes of Respiratory Distress Syndrome in the MeSH hierarchy.
- Respiratory Distress Syndrome, Newborn
26 drugs (18 approved, 8 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (30)
- propofol
- heparin
- urea
- tadalafil
- cisatracurium
- prednisone
- ibuprofen
- betamethasone
- sevoflurane
- albumin (Human)
- hydrocortisone
- nalbuphine
- succinylcholine
- valsartan
- surfactant
- remimazolam
- rocuronium
- sivelestat
- sufentanil
- spironolactone
- ondansetron
- dexmedetomidine
- fentanyl
- budesonide
- midazolam
- sodium chloride
- thymalfasin
- remifentanil
- dexamethasone
- ciprofol
Phase 3 trials (48)
- ringer's lactate
- vitamin d3
- methylprednisolone
- autologous plasma
- butantan
- ketamine
- esmolol
- dornase alfa
- isoflurane
- remdesivir
- hydroxychloroquine
- bone marrow derived mesenchymal stem cells
- porcine lung surfactant
- icosapent ethyl
- iloprost
- levosimendan
- lisofylline
- nitric oxide
- vitamin c
- pirfenidone
- acetaminophen
- lidocaine
- red blood cells
- streptokinase
- immune globulin (human)
- siltuximab
- alteplase
- trans sodium crocetinate
- thyrotropin releasing hormone
- glucose
- +18 more
Phase 2 trials (97)
- roflumilast
- mavrilimumab
- sodium nitrite
- corticotropin
- allostim
- alt-836
- atrial natriuretic peptide
- bio-11006
- bovine lipid extract surfactant
- etanercept
- colfosceril palmitate
- ginger
- imatinib
- naltrexone
- gsk2862277
- ritonavir
- cc10
- insulin human
- helium
- adenosine
- ic14
- ifx-1
- soybean oil
- ganciclovir
- platelet-rich plasma
- pb1046
- perfluorocarbon
- lactose
- formoterol
- prochlorperazine
- +67 more
Phase 1 trials (21)
- sucrose
- acetylcysteine
- defibrotide
- tenecteplase
- Filgrastim
- nitroprusside
- tnx-832
- endotoxin
- vasoactive intestinal peptide
- autologous regulatory t cells
- autologous umbilical cord blood
- inkt cells
- poly-iclc
- bay1211163
- cryopreserved ex vivo expanded polyclonal cd4+cd127lo/-cd25+ t regulatory cells
- lomecel-b
- ev-pure
- wj-pure
- bz371b
- glycolic acid tetrasubstituted piceatannol
- matriplax
Other trials (25)
Organizations
Organization Involved with Phase 4 Indications (50)
- Istanbul University
- ARAIRLOR
- University of Rochester
- Taipei Medical University
- China Medical University
- Merck
- Maternite Regionale Universitaire
- Chang Gung University
- Chung Shan Medical University
- Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
- I.M. Sechenov First Moscow State Medical University
- Consorcio Centro de Investigación Biomédica en Red, M.P.
- Aarhus University
- Mahidol University
- Pontificia Universidad Catolica de Chile
- United States Army
- Taipei Veteran General hospital
- Nanjing Medical University
- Aix-University of Marseille
- Chiesi
- Radboud University
- Mackay Medical College
- Ege University
- Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
- Marche Polytechnic University
- B. Braun
- ONY
- The Gerber Foundation
- Mario Negri Institute
- Cathay General Hospital
- +20 more
Organization Involved with Phase 3 Indications (161)
- Centre Jean Perrin
- Louisiana State University
- University of Minnesota
- Albert Einstein Israelite Hospital
- University of Helsinki
- Ache Laboratorios Farmaceuticos S.A.
- Beni Suef University
- Groupe Hospitalier Diaconesses Croix Saint Simon
- University of Nice Sophia Antipolis
- Shahid Beheshti University of Medical Sciences
- Azad University
- Yale University
- University of Tehran
- University of Ottawa
- University of Tennessee
- University of Franche-Comté
- National Center for Research Resources (NCRR)
- Latter Day Saints Hospital
- Centre Hospitalier de Cannes
- Postgraduate Institute of Medical Education and Research
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
- Royan Institute
- NeuroRx, Inc.
- University of Indonesia
- Centre Hospitalier St Anne
- Laboratoire français de Fractionnement et de Biotechnologies
- Leo Pharma
- Centre Hospitalier de Douai
- Federal University of Juiz de Fora
- Hospital Sirio-Libanes
- +131 more
Organization Involved with Phase 2 Indications (149)
- National Polytechnic Institute, Mexico
- Windtree Therapeutics
- Suntory Pharmaceutical
- GlaxoSmithKline
- Histocell, S.L.
- Iltoo Pharma
- AVM Biotechnology LLC
- LEAF4Life LLC
- Vita-Salute University of Milano. Italy
- Zhejiang University
- Eli Lilly
- Hospital de Cruces
- Food and Drug Administration
- Kinevant Sciences GmbH
- Cartesian Therapeutics
- Winnipeg Rh Institute Foundation Inc.
- Autonomous University of Madrid
- Amyndas Pharmaceuticals S.A.
- Cell Therapy Catapult
- University of Versailles
- University of Colorado
- Medical University of Vienna
- Kyoto Prefectural University of Medicine
- Victoria Infirmary
- Techpool Bio-Pharma Co., Ltd.
- Theravance
- Methodist Research Institute, Indianapolis
- European Society for Paediatric Research
- Virginia Commonwealth University
- The Claude D. Pepper Older Americans Independence Centers
- +119 more
Organization Involved with Phase 1 Indications (30)
- Tanox
- Northern State Medical University
- Jazz Pharmaceuticals
- Longeveron LLC
- Uppsala University
- Medical University of Warsaw
- Shaoxing Second Hospital
- Exvastat Ltd.
- MiNK Therapeutics
- Ain Shams University
- Celerion
- University of Kentucky
- National Institute of Allergy and Infectious Diseases (NIAID)
- Instituto de Medicina Regenerativa
- Northern Norway Regional Health Authority
- Meridigen Biotech Co., Ltd.
- Viela Bio
- Medical Center of Central Georgia
- University of South Carolina
- Government of Italy
- Sun Yat-Sen University
- State University of New York
- Stem Cell Network
- ReAlta Life Sciences, Inc.
- Methodist Cancer Center, Houston, Texas
- Savara Inc.
- Pomeranian Medical University
- National Cancer Institute (NCI)
- Agenus Inc.
- University of Oklahoma
Organization Involved with Other Experimental Indications (45)
- Klinikum Aschaffenburg-Alzenau
- University of Florence
- University of Bonn
- Henan Medical University
- Loma Linda University
- Aga Khan University
- University of Amsterdam
- Hospital of Leverkusen
- Emek Medical Center
- Northwell Health
- Lund University
- Washington University in St. Louis
- University of Hamburg
- Alta Bates Summit Medical Center
- Vestische Kinder- und Jugendklinik Datteln
- Rafael Pharmaceuticals Inc.
- Ruhr University Bochum
- Maple Grove Hospital and North Memorial Hospital
- University of Missouri
- Instituto Nacional de Enfermedades Respiratorias
- Azienda Ospedaliera San Gerardo di Monza
- University of Antwerp
- Qingdao University
- State University of New York, Buffalo
- Kliniken der Stadt Koeln, Kinderkrankenhaus Riehl
- Kilimanjaro Christian Medical College, Tanzania
- Winthrop University
- University of Kansas
- German Federal Ministry of Education and Research
- Monash University
- +15 more